Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to confirm whether SmartVest reimbursement rates lifted Electromed’s margins or to track executive stock sales hidden in Form 4 PDFs can feel like wading through dense technical language and FDA jargon. Electromed’s SEC documents pack clinical trial data, quality-system risks, and payer disclosures into hundreds of pages—precisely the information analysts need yet struggle to find quickly.
Stock Titan’s AI-powered engine decodes every filing the moment it hits EDGAR. Whether you search “Electromed quarterly earnings report 10-Q filing” for unit-sales trends, or “Electromed insider trading Form 4 transactions” to gauge management sentiment, our platform delivers plain-English highlights, context, and red-flag alerts. Real-time feeds push “Electromed Form 4 insider transactions real-time” notices to your dashboard, while concise summaries turn a 300-page annual report into a two-minute brief.
You’ll find every document type in one place:
- 10-K: see SmartVest revenue segments and reimbursement risk factors—“Electromed annual report 10-K simplified”.
- 10-Q: quarter-over-quarter supply-chain costs with “Electromed earnings report filing analysis”.
- 8-K: “Electromed 8-K material events explained” when new clinical data or FDA correspondence surfaces.
- DEF 14A proxy: drill into “Electromed proxy statement executive compensation”.
Stop scrolling line-by-line through EDGAR. From “understanding Electromed SEC documents with AI” to pinpointing “Electromed executive stock transactions Form 4”, our coverage transforms complex disclosures into actionable clarity so you can focus on investment decisions, not document hunting.
Andrew Summers, a director of Electromed, Inc. (ELMD), reported multiple open-market sales of company common stock on September 10 and 11, 2025. The Form 4 shows sales of 39,378, 16,203, 6,576, 404 and 3,153 shares at weighted average prices between $23.6791 and $26.6246, with sale price ranges disclosed for each lot. Some holdings are reported as indirectly owned by investment vehicles (SVP Deal Fund I LP and Summers Value Fund LP), and the filing disclaims direct beneficial ownership except to the extent of pecuniary interest. One reported sale of 3,153 shares on 09/11/2025 reduced the reporting person’s indirect holding in a specified vehicle to 0 shares according to the form. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Electromed, Inc. (ELMD) Form 144 reports a proposed sale of 65,714 shares of common stock via BTIG, LLC on the NYSE American with an aggregate market value of $1,554,136.10. The shares were acquired in the open market on 06/01/2021 and paid for in cash. The filing lists 8,349,176 shares outstanding for the class and shows no securities sold in the past three months. The proposed sale is scheduled for 09/10/2025. The filer affirms there is no undisclosed material adverse information.
Electromed, Inc. (ELMD) Form 4 filed for James L. Cunniff, CEO and President. The filing reports a disposition of 1,291 common shares on 09/02/2025 at $23.95 per share to satisfy tax withholding related to vested restricted stock, reducing his holdings to 130,751 shares. On the same date he was granted 17,000 restricted shares scheduled to vest in three equal annual installments beginning September 2026, and received an employee stock option for 31,100 shares at a $23.95 exercise price exercisable in three equal annual installments beginning September 2026 and expiring 09/02/2035, leaving 31,100 options outstanding.
Electromed, Inc. (ELMD) reporting person Bradley M. Nagel, CFO, made scheduled equity transactions on 09/02/2025 that increased his overall beneficial stake. He disposed of 562 common shares to satisfy tax withholding from restricted stock vesting at an average price of $23.95, leaving him with 16,538 shares prior to additional acquisitions. He acquired 5,300 restricted shares (no cash price) that vest in three equal annual installments beginning September 2026, and received an employee stock option to buy 9,800 shares at a $23.95 exercise price expiring 09/02/2035, vesting in three equal annual installments from September 2026. After the transactions, his beneficial ownership rose to 21,838 common shares plus 9,800 option shares exercisable in the future.
Electromed, Inc. reported details in its Form 10-K that describe its business, capital structure and selected balance sheet and operating items. The company had 8,349,176 shares issued and outstanding as of June 30, 2025, down from 8,637,883 a year earlier after share repurchase programs that retired 280,017 and 220,899 shares in prior authorizations for total costs of $5,000,000 each and are now exhausted. The company maintains a $2.5 million secured line of credit with interest at prime less 1.0% (prime was 7.50% at June 30, 2025). Operating lease liabilities increased to $198,000 from $87,000 and related right-of-use assets and lease terms are disclosed. As of June 30, 2025, unrecognized compensation expense related to non-vested awards was $1,351,000 expected to be recognized over weighted-average periods near two years. The effective tax rates were 26.7% and 26.8% for fiscal 2025 and 2024. The Audit Committee and Board provide oversight of a cybersecurity risk management program co-led by senior management and third-party providers.
Electromed, Inc. disclosed that it has issued a press release reporting its financial results for the fourth quarter and fiscal year ended June 30, 2025, and furnished that press release as Exhibit 99.1 to this Form 8-K. The company also updated its investor presentation and furnished it as Exhibit 99.2, noting that the presentation may be used in meetings with investors and analysts.
The filing provides notice that the company has made results and updated presentation materials available to the market, but it does not include the financial metrics or narrative from the press release within the filing itself; interested parties must refer to the referenced exhibits for the detailed results and figures.